Market Overview

Deciphera Pharma Scores A Sell-Side Recommendation

Share:
Deciphera Pharma Scores A Sell-Side Recommendation

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)’s kinase switch control platform has largely gone unnoticed on the Street.

The nascent portfolio caught an analyst's attention this week. 

The Rating

B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43 price target.

The Thesis

The analyst expects Deciphera’s DCC-2618 to post positive Phase 3 results in fourth-line gastrointestinal stromal tumors in 2019 and to start Phase 3 studies for second-line GIST in the latter half of 2018.

Phase 1 studies for the fourth-line indication demonstrated efficacy in disease control rate and early progression-free survival data. Early results in the second-line indication lend additional confidence in success against Pfizer Inc. (NYSE: PFE)’s Sutent.

“Consequently, the second-line opportunity for DCC-2618 could provide a critical edge in the GIST market, particularly in relation to competing c-Kit/PDGFRα TKI avapritinib from Blueprint Medicines Corp (NASDAQ: BPMC), for which Phase 3 studies in third-line GIST, versus Stivarga from Bayer, are guided to start in the first half of 2018,” Kumar said in a Thursday note.

“Taken as a whole, we see a broader opportunity for DCC-2618 in GIST in the second-line setting.”

Price Action

At the time of publication, Deciphera shares were up 0.8 percent at $28.93.

Related Links:

Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs

Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight

Latest Ratings for DCPH

DateFirmActionFromTo
Sep 2020SVB LeerinkMaintainsMarket Perform
Aug 2020SVB LeerinkMaintainsMarket Perform
May 2020SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for DCPH
View the Latest Analyst Ratings

 

Related Articles (DCPH)

View Comments and Join the Discussion!

Posted-In: B Riley Madhu KumarAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
ZZZScotiaBankMaintains27.0
FSVScotiaBankMaintains128.0
FNScotiaBankMaintains38.0
CSUScotiaBankMaintains1,600.0
CXOScotiaBankDowngrades43.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com